Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The optimal valve substitute for patients between 60-70 years is controversial. We compared anticoagulation-related adverse events (ARAE) in patients receiving mechanical heart valve replacement (MHVR) on INR self-management vs. stentless bioprosthesis, to assess whether the risk of structural valve deterioration (SVD) is still out-weighted by the benefit of not requiring permanent anticoagulation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | Group A patients received mechanical heart valve replacement MHVR (and were educated in INR self-management using the Coagu-Check monitor. | ||
| Group B | Group B patients received MHVR and their anticoagulation was managed by their general practitioners. | ||
| Group C | Group C patients received stentless bioprosthesis, with initial 6 weeks on oral anticoagulation managed by their general practitioners. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients received heart valve replacement and were retrospectively allocated in three groups
Not provided
Not provided
Not provided
Not provided